01273 704473

info@novuscomms.com

01273 704473

info@novuscomms.com

#HVO hVIVO PLC – Appointment of Non-Executive Director December 18, 2025 – Posted in: hVIVO (HVO)

hVIVO plc (AIM: HVO), a full-service early phase Contract Research Organisation (CRO) and the world leader in human challenge clinical trials, announces the appointment of Richard Cotton as Independent Non-Executive Director, effective today. Richard will also serve as Chair of the Audit Committee and as a member of the Remuneration and Nominations Committees.   Richard brings extensive Board-level and financial expertise, including experience serving as Chair, Audit Chair and Senior Independent Director, as well as holding advisory…

Continue reading

#VELA Vela Technologies PLC – Interim Results December 22, 2023 – Posted in: Blog, Vela Technologies Plc (VELA)

Vela Technologies plc (AIM: VELA), an AIM-quoted investing company focused on early stage and pre-IPO disruptive technology investments, is pleased to announce its interim results for the six months ended 30 September 2023. Overview The last six months have continued to be challenging for capital markets with political unrest continuing both at home and abroad, the continuing war in Ukraine and rising inflation and interest rates continue to be factors impacting the small-cap marketplace in…

Continue reading

#POLB Poolbeg Pharma – Poolbeg Partners with a Nasdaq-Listed Biopharma October 17, 2023 – Posted in: Poolbeg Pharma (POLB)

Poolbeg Pharma Partners with a Nasdaq-Listed Biopharma Company on its Oral Delivery Platform   Strategic collaboration focussed on the development of an optimised drug for a metabolic condition using Poolbeg’s licensed oral delivery technology   Collaboration may expand to a full licensing agreement   17 October 2023 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company targeting diseases with a high unmet medical need, announces that it has signed a strategic collaboration agreement…

Continue reading

#VELA Vela Technologies PLC – Final results for the year ended 31 March 2023 September 28, 2023 – Posted in: Blog, Vela Technologies Plc (VELA)

The Board of Vela (AIM:VELA), an AIM-quoted investing company focused on early-stage and pre-IPO disruptive technology investments, is pleased to announce the Company’s final results for the year ended 31 March 2023. Vela’s Annual Report and Accounts for the year ended 31 March 2023 (“Annual Report”) will be sent to shareholders today. The Company’s Annual Report will be available shortly on the Company’s website at http://www.velatechplc.com/ Highlights Financial: ·      Net assets decreased to £7,004,480 compared…

Continue reading

#VELA Vela Technologies PLC – Update re. Economic Interest in AZD1656 August 15, 2023 – Posted in: Blog, Vela Technologies Plc (VELA)

Further to the Company’s announcement on 15 May 2023, the Board of Vela (AIM: VELA), an AIM-quoted investing company focused on early-stage and pre-IPO disruptive technology investments, notes that Murphy Canyon Acquisition Corp. (NASDAQ: MURF) (“Murphy”) has now received a notice of effectiveness from the United States Securities and Exchange Commission (“SEC”) which can be found here: https://www.sec.gov/Archives/edgar/data/1896212/999999999523002356/xslEFFECTX01/primary_doc.xml.   As such, Murphy has formally notified its current shareholders that a special meeting will be held…

Continue reading

UK Investor Magazine Podcast -CEO Alan Green discusses AstraZeneca, Georgia Capital and Vela Technologies November 10, 2022 – Posted in: Blog, Uncategorized

Alan Green joins the Podcast as we delve into key markets theme and a number of UK equities. We discuss: AstraZeneca (LON:AZN) Georgia Capital (LON:CGEO) Vela Technologies (LON:VELA) We start by looking at potential catalysts for markets as we move into the winter. AstraZeneca has reported a solid set of third quarter results as the company sees the benefits of higher cancer drug sales. Georgia Capital has been trading at deep discount to NAV and…

Continue reading

Tekcapital #TEK – CEO Clifford Gross talks progress to date with Alan Green, including the Lucyd Nasdaq IPO August 17, 2022 – Posted in: Blog

Tekcapital #TEK – CEO Clifford Gross talks progress to date with Alan Green, including the Lucyd Nasdaq IPO. Clifford talks through the recent full year results, the substantial growth in NAV and the share price performance. We then look at Tekcapital’s global discovery network, before looking at the four key investments held by the company, including Lucyd, Belluscura, Guident and Salarius (Microsalt). We end by looking at the progress to date, including client list, client…

Continue reading